Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Pancreatic Neoplasms 43Carcinoma, Non-Small-Cell Lung 35Breast Neoplasms 35Triple Negative Breast Neoplasms 16Neoplasms 15Neoplasm Metastasis 14Carcinoma 9Adenocarcinoma 9Lung Neoplasms 7Head and Neck Neoplasms 6Colorectal Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Pancreatic Diseases 5Cholangiocarcinoma 5Carcinoma, Squamous Cell 5Neoplasms by Site 4Melanoma 4Digestive System Neoplasms 4Digestive System Diseases 4Sarcoma 3Pancreatic Adenocarcinoma 3Neoplasms by Histologic Type 3Inflammatory Breast Neoplasms 3Endocrine System Diseases 3Endocrine Gland Neoplasms 3Carcinoma, Pancreatic Ductal 3Carcinoma, Ovarian Epithelial 3Uveal Melanoma 2Urinary Bladder Neoplasms 2

Interventions

pembrolizumab 26atezolizumab 14Nivolumab 13Gemcitabine 13Cisplatin 10Docetaxel 8Carboplatin 8avelumab 7Mitomycin 7epacadostat 4cabozantinib 4Ipilimumab 4pemigatinib 3Specimen Handling 3Paclitaxel 3Magnetic Resonance Spectroscopy 3Bevacizumab 3vofatamab 2rucaparib 2lenvatinib 2enfortumab vedotin 2durvalumab 2cabazitaxel 2bempegaldesleukin 2Standard of Care 2Rogaratinib 2Ramucirumab 2Radiation 2Platinum 2Pemetrexed 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Transitional Cell × 130-nm albumin-bound paclitaxel × Clear all
NCT02887248 2023-12-05

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

SCRI Development Innovations, LLC

Phase 2 Terminated
3 enrolled 9 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡